One of the complications of multiple myeloma is the development of lytic bone lesions. Learn about the causes, symptoms and management of bone lesions associated with multiple myeloma at WebMD.

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

Multiple myeloma can lead to bone lesions. Learn more about how they develop, how doctors treat them, and a person's outlook.

The team tackled a critical challenge in treating multiple myeloma—a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Multiple myeloma can cause you to have bone pains and weak or easily broken bones. Caring for your bones is an important part of your treatment plan that can significantly improve your health ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

The team tackled a critical challenge in treating multiple myeloma -- a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Patients with multiple myeloma often develop bone lesions resulting in skeletal-related events (SREs), such as spinal cord compression, vertebral collapse, pathologic fractures and bone pain. Bone ...

Approximately 90 percent of people with multiple myeloma will develop these lytic bone lesions, according to research. They can occur anywhere, but the spine, rib cage, and pelvis are most likely ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The ...

The team tackled a critical challenge in treating multiple myeloma—a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.